bullish

Oncopeptides

Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising

84 Views06 Nov 2025 14:10
Syndicated
Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.
What is covered in the Full Insight:
  • Investment Thesis
  • Review of the quarter
  • Quarterly financials
  • Valuation
  • Redeye Quality Rating
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 17-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising
    06 Nov 2025
x